Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study

RecruitingOBSERVATIONAL
Enrollment

5

Participants

Timeline

Start Date

March 14, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
Huntington DiseaseHuntington's DementiaHuntington Disease, Late OnsetHuntington; Dementia (Etiology)
Interventions
OTHER

Biospecimen Collection

"Cohort 1-Huntington's Disease:~The target blood volume of each phlebotomy visit will be 20 mL. The minimum accepted volume (in the event of tough venipuncture attempts or difficulty obtaining the blood) will be 5 mL. The maximum amount that can be drawn in a 6-week period will be 100 mL (whole blood 6-week maximum).~Sample Collection:~* 10 mL EDTA Vial (Box 1; Frozen)~ o Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped frozen (on dry ice) FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 1.~* 10 mL EDTA Vial (Box 2; Ambient)~ * Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped ambient FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 2."

Trial Locations (1)

01801

RECRUITING

Sanguine Biosciences, Inc., Woburn

Sponsors
All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Sanguine Biosciences

INDUSTRY

NCT05773196 - Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study | Biotech Hunter | Biotech Hunter